Nestlé to Acquire Aimmune Therapeutics for $2.6B

Share this
Nestlé to Acquire Aimmune Therapeutics for $2.6B

Nestlé to Acquire Aimmune Therapeutics for $2.6B


  • Nestle to acquire all outstanding shares of Aimmune’s common stock for $34.50/share in cash- making a total deal value as $2.6B- representing a 174% premium to Aimmune's closing share price on Aug 28- 2020- of $12.60. The transaction is expected to close in Q4’20
  • The acquisition extends Nestle’s food allergy portfolio with the addition of Palforzia- creating a broader spectrum of solutions for children living with food allergies
  • Aimmune's Palforzia is the first and only FDA-approved treatment- which helps in reducing the frequency and severity of the allergic reaction to peanuts- including anaphylaxis- in children aged 4-17yrs.

­ Ref: Aimmune | Image: Aimmune

Click here to­ read the full press release 


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions